Behind the medicines we make are real names and real stories. Meet some of the people we innovate for every day. https://bit.ly/4onBTKY
About us
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
- Website
-
http://www.abbvie.com
External link for AbbVie
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- North Chicago, Illinois
- Type
- Public Company
- Specialties
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care
Locations
Employees at AbbVie
Updates
-
ICYMI: Members of our executive leadership team discussed our Q2 2025 #FinancialResults during last week’s #earnings call. Swipe to learn more about our performance from our leaders. Click here to read our results: https://lnkd.in/gVyvS3tp $ABBV #earnings [Image description: Members of AbbVie’s executive leadership team share their remarks on our Q2 Financial Results, including: Robert A. Michael, Jeffrey R. Stewart, Roopal Thakkar, and Scott T. Reents.]
-
Happy #NationalInternDay to our 210 interns, from 88 schools, joining us across 11 U.S. locations this summer. Thanks for your curiosity, collaboration and contributions to help advance our mission of enhancing people’s lives. Interested in our student programs? Learn more here: https://bit.ly/45usPMT #AbbVieLife
-
-
"AbbVie delivered another outstanding quarter with strong performance from our diversified growth platform," said Robert A. Michael, our Chairman of the Board and CEO. Our Q2 2025 #FinancialResults are in. Read them here: https://bit.ly/3H0KxhR $ABBV #earnings [Video description: AbbVie logo followed by graph animations, with text reading, “Q2 2025 Financial Results.”]
-
NEWS: Today we announced topline results from our Phase 3 study in #AlopeciaAreata. Learn how this study underscores our commitment to improving the lives of people living with immune-mediated diseases where the burden of disease is significant and treatment options remain limited. Read more: https://bit.ly/4l1lM2Q #immunology [Video description: On-screen text reads, “Immunology News”]
-
Recently, we hosted a Life in Freedom panel discussion, bringing together patient advocates and key opinion leaders, to discuss how we can achieve better outcomes for people living with chronic lymphocytic leukemia (#CLL). Moderated by our own Fernando Tatsch, MD, MBA, patient advocates and experts in the CLL space across the globe attended for a vibrant exchange around the importance of shared decision-making between CLL patients and their care teams. Thank you to everyone who participated and made the event a success.
-
-
Did you know: #HepatitisC increases the risk of #LiverCancer? The tools to eliminate #HCV exist, but action is needed to increase testing and treatment services around the world. On #WorldHepatitisDay, join us and The World Hepatitis Alliance in raising awareness of the impact of HCV and the importance of advancing care in the global community: https://bit.ly/459THR8 [Video description: Interview with Rachel Halford, President of World Hepatitis Alliance & former HCV patient. On-screen text reads, “Achieving HCV elimination goals would avert 1.5 million deaths from HCV alone over the next decade. Join us in helping move the world closer to eliminating Hepatitis C.”]
-
What does it mean for an antibody to take on multiple targets at once? 🎯 In this One Minute Thesis, watch one of our #scientists explain how #MultispecificAntibodies may help create new treatment approaches. [Video description: An AbbVie scientist in the lab explains how multispecific antibodies work. On-screen text reads, “One Minute Thesis, Multispecific Antibodies.”]
-
That's a wrap on AbbVie In Motion, our annual 4-week virtual fitness challenge for employees. This year’s theme, "Get Outside for '25," encouraged employees to spend at least 25 minutes outside – walking, running, biking, hiking and more. More than 19,000 participants logged more than 29 million activity minutes – equal to running 550,000 marathons. AbbVie In Motion aims to help our employees be at their best by promoting health, well-being and connection. Thanks to all who participated and helped make this year's challenge a success. #AbbVieLife [Video description: On-screen text highlights key results from this year’s AbbVie In Motion along with images of employees participating in activities such as running, riding bikes, playing pickleball and more.]
-
NEWS: We recently announced a licensing agreement with Ichnos Glenmark Innovation (IGI) for a trispecific antibody currently in development for #MultipleMyeloma. This agreement reinforces our commitment to advance novel therapies, including multispecific antibodies for people living with #cancer. Learn more here: https://bit.ly/44APaa0 [Video description: On-screen text reads, "Oncology News."]